Daraxonrasib Pill Hailed as Major Breakthrough for Advanced Pancreatic Cancer
A KRAS inhibitor pill called daraxonrasib halted tumour growth in 90% of advanced pancreatic cancer patients during a 61-person trial, with a one-year survival rate of 76.6% compared to 40-45% for chemotherapy alone.
A pill called daraxonrasib is being hailed as the biggest breakthrough treatment for pancreatic cancer in decades. The drug, a KRAS inhibitor that works by shutting off mutations found in most pancreatic cancers, demonstrated significant results in a clinical trial involving 61 patients with advanced disease.

During the trial, tumours stopped growing in 90% of participants. Just over 60% of patients saw their tumours shrink or disappear entirely, and in about 8% of cases—roughly one in 12 patients—tumours became undetectable on CT scans. One year after starting treatment, 76.6% of patients were alive. This marks a substantial improvement over the typical 40-45% one-year survival rate for patients given chemotherapy alone. The median follow-up period for patients in the trial was 18 months.
Dr Wungki Park presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Dr Park is affiliated with Memorial Sloan Kettering Cancer Center in New York.
The results are particularly notable given the severity of the disease. Half of all people diagnosed with pancreatic cancer die within three months, and only about 3% survive five years when the disease has spread.

While daraxonrasib is not yet considered a confirmed cure, it offers the potential for longer disease control and survival for pancreatic cancer patients. There is also hope that the drug may be used to treat other cancers driven by similar KRAS mutations. Organizations including Cancer Research UK and the NHS have noted the encouraging nature of the news.